Teerlink JR, Davison BA, Cotter G, et al. - Given six randomized, controlled clinical trials have assessed the effectiveness as well as safety of 48 h intravenous 30 μg/kg/day serelaxin infusion in acute heart failure (AHF), researchers performed a fixed-effect meta-analysis with all investigations of intravenous serelaxin started within the first 16 h of admission for AHF. The primary and secondary endpoints tested in the serelaxin phase III investigations were regarded as endpoints. Overall 6,105 patients were randomized to receive intravenous serelaxin 30 μg/kg/day and 5,254 to control in six randomized controlled trials. Findings revealed a highly significant decrease in the risk of 5-day worsening heart failure and in alterations in renal function markers in relation to administration of intravenous serelaxin to patients admitted for AHF, however, this treatment had no statistically significant influence on length of stay, or cardiovascular death, or heart or renal failure rehospitalization. Treatment with serelaxin was proved to be safe and was related to a significant decrease in all-cause mortality.